MannKind | MNKD - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Adma Biologics USD 20.19M 2.86M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 54.08M 4.33M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Novavax USD 25.53M 1.34M 2025-12
Novo Nordisk DKK 2.86B 13.25B 2025-06
Pfizer USD 2.92B 1.16B 2026-03
Sanofi EUR 2.33B 419M 2026-03
Xencor USD 82.12M 65.08M 2026-03